Screener
Immix Biopharma, Inc. IMMX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Total other income (expense), net | 717,168 | 150,219 |
| Loss before provision for income taxes | (10,086,687) | (4,532,706) |
| Provision for income taxes | - | 9,822 |
| Net loss | (10,086,687) | (4,542,528) |
| Other comprehensive income: | ||
| Unrealized gains on available-for-sale securities | 69,141 | - |
| Foreign currency translation | (23,665) | 16,519 |
| Total other comprehensive income | 45,476 | 16,519 |
Document
FAQ
- What is Immix Biopharma, Inc.'s net income?
- Immix Biopharma, Inc. (IMMX) reported net income of -$10.09M in Q1 2026.
- How has Immix Biopharma, Inc.'s net income changed year-over-year?
- Immix Biopharma, Inc.'s net income decreased by 122.1% year-over-year, from -$4.54M to -$10.09M.
- What is the long-term trend for Immix Biopharma, Inc.'s net income?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s net income has grown at a 4.8% compound annual growth rate (CAGR), from -$24.38M to -$29.4M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Immix Biopharma, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude